Sentinel lymph node biopsy is associated with breast cancer rates

The incidence of some early stage metastatic breast cancers is increasing, but this finding is likely explained by changes in clinical practice, according to a study published online June 26 in the Journal of the National Cancer Institute.

Deirdre Cronin-Fenton, Ph.D., of Aarhus University Hospital in Denmark, with colleagues at the National Cancer Institute in Bethesda, Md., found that the increase in some early stage breast cancers corresponded to greater use of biopsies of sentinel lymph nodes—the primary lymph node to which cancer cells are likely to spread from a tumor. Sentinel lymph node biopsies often detect small numbers of tumor cells that do not necessarily indicate that the cancer has spread.

“While the use of [sentinel lymph node biopsy] in community practice continues to increase, it is expected that cases with [lymph node] metastases also will continue to increase,” the authors write.

Contact: Brenda Edwards, surveillance research program, National Cancer Institute, (301) 496-8506, edwardsbk@mail.nih.gov

Citation: Cronin-Fenton DP, Ries LA, Clegg LX, Edwards BK. Rising Incidence Rates of Breast Carcinoma With Micrometastatic Lymph Node Involvement. J Natl Cancer Inst 2007; 99: 1044-1049

Note to Reporters:

We may be starting up an e-mail list to alert reporters when papers are available on the EurekAlert site. If you would be interested on being on this list, please let us know at jncimedia@oxfordjournals.org. The content will continue to be available through EurekAlert’s e-mail system and our EurekAlert page.

The Journal of the National Cancer Institute is published by Oxford University Press and is not affiliated with the National Cancer Institute. Attribution to the Journal of the National Cancer Institute is requested in all news coverage. Visit the Journal online at http://jnci.oxfordjournals.org/.